
Opinion|Videos|September 25, 2024
Guiding Patients Through Third-Line mCRC Therapy Decisions
Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
When discussing treatment selection in the third-line setting for metastatic colorectal cancer, how do you frame this conversation with patients, balancing efficacy, safety, and overall prognosis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5

















